Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents - A report of two cases

Annals of the Academy of Medicine Singapore

Volumn 40, Issue 6, 2011, Pages 287-290

  Lingegowda, Pushpalatha B ^a   Tan, Chee Kiat ^a   Tan, Ai Ling ^a   Tan, Ban Hock ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Caspofungin; Echinocandin; Fluconazole resistance; Liver transplantation; Trichosporon; Voriconazole

Indexed keywords

BASILIXIMAB; CASPOFUNGIN; CEFEPIME; FLUCONAZOLE; HYDROCORTISONE; ITRACONAZOLE; LEVOFLOXACIN; MEROPENEM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; POSACONAZOLE; VANCOMYCIN; VORICONAZOLE;

ADULT; ANTIFUNGAL RESISTANCE; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CANDIDIASIS; CASE REPORT; CLAVISPORA LUSITANIAE; DISSEMINATED TRICHOSPORONOSIS; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FUNGAL COLONIZATION; FUNGEMIA; GRAFT INFECTION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEPSIS; STENOTROPHOMONAS MALTOPHILIA; TRICHOSPORON ASAHII; TRICHOSPORONOSIS;

EID: 79960148102     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rabkin JM, Oroloff SL, Corless CL, Benner KG, Flora KD, Rosen HR, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000;179:426-30.
2. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004;39:S200-6.
3. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008;8:426-31.
4. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006;12:850-8.
5. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005;80:868-71.
6. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9.
7. Fortun J, Martin-Davila P, Montejo M, Munoz P, Cisneros JM, Ramos A, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009;87:424-35.
8. Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002;35:e35-6.
9. Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough Trichosporon asahii fungemia in a neutropenic patient with acute leukemia while receiving caspofungin. Infection 2008;36:68-70.
10. Ness MJ, Markin RS, Wood RP, Shaw BW jr, Woods GL. Disseminated Trichosporon beigelii infection after orthotopic liver transplantation. Am J Clin Pathol 1989;92:119-23.
11. Finkelstein R, Singer P, Lefler E. Catheter related fungemia caused by Trichosporon beigelii in non-neutropenic patients. Am J Med 1989;86:133.
12. Abdala E, Lopes RI, Chaves CN, Heins-Vaccari EM, Shikanai-Yasuda MA. Trichosporon asahii fatal infection in a non-neutropenic patient after orthotopic liver transplantation. Transpl Infect Dis 2005;7:162-5.
13. Da Silva Rodrigues G, Ubatuba de Faria R, Silva Guazzelli L, de Mattos Oliveira F, Severo L. Infeccio'n nosocomial por Trichosporon asahii: revision clinica de 22 casos. Rev Iberoam Micol 2006;23:85-9.
14. Biasoli MS, Carlson D, Chiganer GJ, Parodi R, Greca A, Tosello ME, et al. Systemic infection caused by Trichosporon asahii in a patient with liver transplant. Med Mycol 2008;46:719-23.
15. Lacasse A, Cleveland KO. Trichosporon mucoides fungemia in a liver transplant recipient: case report and review. Transpl Infect Dis 2009;11:155-9.
16. Sun HY, Singh N. Characterization of breakthrough invasive mycoses in echinocandin recipients: an evidence based review. Int J Antimicrob Agents 2010;35:211-8.
17. Fortun J, Lopez-San Roman A, Velasco JJ, Sanchez-Sousa A, de Vicente E, Nuno J, et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 1997;16:314-8.
18. Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother 2005;49:783-7.
19. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006;44:1740-3.
20. Doria C, Bodzin AS, Vaccino S, Daskalakis C, Krawitz S, Ramirez CB. A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin. Clin Transplant 2010:Jul 21.[Epub ahead of print]